Senior Computational Biologist

Cambridge, Massachusetts, US
Jul 14, 2021
Aug 02, 2021
Employment Type
Full time
Salary Type
Job Description
Why join us?

FogPharma® is pioneering the discovery, development, and commercialization of HeliconTM peptides, an exciting new drug modality that uniquely combines the cell-permeability of traditional small molecule drugs with the specificity, broad target accessibility and discovery speed of monoclonal antibody drugs. Our patented Helicon peptide technology allows us to modulate the activity of well-known intracellular disease drivers that have thus far evaded small molecule and biologic therapies.

FogPharma's lead program targets beta-catenin, a cancer driver in the WNT pathway. Inhibition of beta catenin has the potential to benefit more than one-fifth of all cancer patients, and is just one of many opportunities for Fog's lead-discovery platform to change future medicines, therapies and lives.

Earlier this year, we closed on a $107M Series C Financing. The oversubscribed round led by top-tier investors is a testament to our speed, scalability and near-term trajectory in getting to the clinic.

What's the opportunity?

We are seeking a Senior Computational Biologist work closely with our Biology group to understand the impact of our compounds on cells and animals. Additionally, you will help guide the selection of cell lines and model animal systems to test our compounds, identify PD and patient selection biomarkers, and support our programs as they march towards the clinic. You will work with internally-generated and public transcriptomic and genomic datasets.

You will
  • Drive the design, analysis, and interpretation of NGS- and proteomics-based experiments to characterize the activity of our compounds in cells and in vivo.
  • Integrate data from multiple internal and external sources to identify and select new targets, discover biomarkers, and define patient populations.
  • Be an authoritative source of knowledge on the best methods for NGS analysis and experimental design.
  • Leverage externally developed tools or develop custom solutions to meet analysis, data visualization, and reporting needs.

What you will need to be successful in this role:
  • Ph.D. in Bioinformatics or Computational Biology
  • 5+ years of experience in the biotech or pharmaceutical industry
  • Expertise in common bioinformatics tools for analysis of NGS (RNAseq, DNAseq) and proteomics data sets
  • Experience in cancer genomics in support of preclinical and translational studies is preferred
  • Strong R programming skills
  • Familiarity with databases/portals such as TCGA, cBioportal PCAWG, ICGC, Depmap, DRIVE and ACHILLES and experience extracting and integrating data to solve scientific challenges
  • Track record of accomplishment demonstrated by peer reviewed publications, inventorship on patent applications and/or invited speakership at major conferences
  • Excellent written and oral communication skills
  • Ready to undertake a "moonshot mission," and work in a fast-paced, highly collaborative, and matrixed environment

As an equal opportunity employer, Fog values diversity and welcomes applicants of all backgrounds and experiences. All qualified applicants will receive consideration for employment without discrimination on the basis of race, color, religion, sex, sexual orientation, gender identity, national origin, protected veteran status, disability, or any other factors prohibited by law.
Company DescriptionFogPharma was founded by renowned life scientist, inventor, pharmaceutical entrepreneur, and biotech company builder Gregory Verdine, with the goal of radically improving treatment outcomes in cancer patients by targeting disease drivers previously believed to be "undruggable." The company is pioneering a new drug modality, cell-penetrating mini-proteins (CPMP), invented by Verdine and his team members at Harvard University and FogPharma to provide drugs that uniquely combine the broad target-engagement power of biologic drugs with the cell-entry capabilities of small molecules. The lead program, direct-acting beta-catenin antagonists, is expected to provide first-in-class drugs having a unique profile, acting both to ablate multiple intractable cancer types harboring activating mutations in the Wnt pathway, and to also stimulate T-cell infiltration into many solid tumors that at present are poorly responsive to immunotherapy. Additional programs targeting other highly validated targets are also being pursued by the company.